clinical trial · NCT07111988
Valbenazine in Obsessive Compulsive Disorder
University of Chicago·phase2·not yet recruiting·n = 30
Obsessive-Compulsive DisorderValbenazinePlacebo
brief summary
The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).
started
May 1, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
May 4, 2026
detailed description
The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD). Subjects will either receive double-blind valbenazine or inactive placebo for 6 weeks. This will be followed by a 2-week washout period and then 6 weeks of being assigned to the other agent (valbenazine or placebo). The hypothesis to be tested is that valbenazine will significantly improve symptoms of OCD compared to placebo.
official title
Valbenazine in Obsessive-compulsive Disorder: A Randomized Double-blind Placebo-controlled Crossover Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol